Novo Nordisk (NVO)
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Lars F. Jørgensen |
| Employees: | 54,400 |
| Web site: | novonordisk.com |
| NOVO ALLE DK 2880, BAGSVAERD DENMARK, Denmark 4544448888 | |
| Date | Ratio |
|---|---|
| 2001-04-11 | 2.5000 |
| 2007-12-17 | 2:1 |
| 2014-01-09 | 5:1 |
| 2023-09-20 | 2:1 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Please log in first to see chart